Lineage Cell Therapeutics (LCTX) to Release Earnings on Thursday

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) is projected to issue its quarterly earnings data before the market opens on Thursday, March 6th. Analysts expect the company to announce earnings of ($0.04) per share and revenue of $1.62 million for the quarter.

Lineage Cell Therapeutics Stock Performance

LCTX stock opened at $0.63 on Thursday. The stock has a market cap of $138.09 million, a PE ratio of -5.22 and a beta of 1.21. Lineage Cell Therapeutics has a twelve month low of $0.48 and a twelve month high of $1.61.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on LCTX shares. D. Boral Capital reduced their target price on Lineage Cell Therapeutics from $3.00 to $2.00 and set a “buy” rating on the stock in a report on Tuesday, February 11th. Maxim Group reduced their price objective on Lineage Cell Therapeutics from $5.00 to $3.00 and set a “buy” rating on the stock in a research note on Friday, January 10th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $9.00 price objective on shares of Lineage Cell Therapeutics in a report on Tuesday, February 11th.

Lineage Cell Therapeutics Company Profile

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.